Status: Not yet recruiting
Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma
This is a window of opportunity study designed to provide short duration exposure to camizestrant prior to planned curative intent surgery, with the anticipated benefit of demonstrating target engagement and suppression of ER signalling in ER positive endometrial cancer without delaying standard surgical management.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: University Health Network, TorontoUpdated: Sep 25, 2026Locations: 6
Eligibility criteria
Participants must provide informed consent prior to undergoing any study-specifi... [+15]
Participants must not have received any previous systemic or local treatment for... [+15]